A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors

Trial Profile

A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Lirilumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 11 Oct 2016 Results of this trial and other (CA223-001; NCT01714739) trial presented at the 41st European Society for Medical Oncology Congress
    • 09 Oct 2016 Results published in the Bristol-Myers Squibb Media Release
    • 09 Oct 2016 According to a Bristol-Myers Squibb media release, safety data from CA223-001 and CA223-002 trials presented at ESMO 2016 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top